Digital Health IPO Revival: Many Startups Still Unprepared for Market Launch

Digital Health IPO Revival: Many Startups Still Unprepared for Market Launch

After a prolonged dry spell of three years, the digital health sector is seeing the beginnings of an IPO resurgence with Hinge Health and Omada Health leading the way. However, a deluge of public offerings from digital health companies isn't anticipated in the immediate future.

Insiders in the investment and banking arenas have expressed to Business Insider that they foresee a scarcity of digital health startups entering the public market at least until 2026.

The debut of Hinge Health, which focuses on physical therapy, and Omada Health, a provider of chronic care, in the first part of the year has caused a notable rise in their stock prices. This promising development suggests that public investors may be opening up to acquiring fresh healthcare stocks, offering a glimmer of hope to numerous private healthcare enterprises seeking exits.

Despite this, the buzz around additional healthcare IPOs has been minimal. According to Rob Stowe, who leads the Americas equity capital markets at Barclays, this caution is partly because some startups are waiting for others to successfully navigate the IPO process before making their moves.

Stowe notes, "A significant number of businesses had not prepared for the current IPO climate and weren't ready for it. Those who ventured into the market deserved recognition as they preemptively prepared rather than merely following the footsteps of other thriving IPOs."

Several ventures that dared to enter the public domain earlier in the year have seen positive outcomes. Hinge Health, for instance, witnessed its market valuation soar over 40% higher than its IPO price, despite still not reaching its peak private market value. Meanwhile, outside the healthcare field, companies like Circle, an issuer of stablecoin, and CoreWeave, a cloud computing brand, have experienced significant post-IPO share increases, signaling revived investor interest across various sectors.

With public offerings by Hinge Health and Omada Health, late-stage healthcare startups can now consider IPOs as viable exits, but only those with strong financial setups should take this path. Given the tight criteria for going public, coupled with ongoing market volatility and the extensive preparations required for entering the public market, the majority of these startups are targeting 2026 or later for their exits, according to industry experts from BI.

Aaron DeGagne, a senior healthcare analyst at PitchBook, expressed, "In the coming 12 to 18 months, we might observe more listings, although the near timing of such events remains uncertain."

Challenges and Preparation for IPO

One might have expected the resurgence of digital health IPOs to lead to a wave of companies going public, given that the IPO market hadn't been favorable to healthcare startups since 2021, but that hasn’t been the case.

Numerous companies have been on standby to issue their IPOs since the market window shut in 2022. Hinge Health, for instance, which went public recently, had stated aspirations back in 2021 to launch an IPO by 2022 following a $300 million Series D round. Similarly, Included Health had aimed for a 2022 IPO, as CEO Owen Tripp confirmed its confidential S-1 filing earlier.

Yet, the tumultuous market landscape prevents a spontaneous IPO despite an apparent reopening. Initiating the public offering process needs significant groundwork; as per Stowe, proceeding from decision to IPO date demands at least half a year of preparation. The entire setup often consumes over a year.

For enterprises that postponed until Hinge Health and Omada Health made their public debuts, the nearest opportunity for such companies to go public would be late 2025.

Market uncertainties, like tariffs shifting under President Trump, add to healthcare companies' hesitations, potentially delaying IPO aspirations. Medline, a firm manufacturing in China, remains cautious, having secretly filed its S-1 last December.

Morgan Cheatham from Breyer Capital noted the lack of healthcare startups moving toward IPOs this year, suggesting many might choose mergers or acquisitions as alternative exits if the public market isn't an immediate option. "Many companies are engaged in discussions about merging rather than becoming acquisition targets," he elaborated.

The Strain of IPO Standards

Despite some signs of optimism, not all healthcare startups are primed for an IPO.

Stowe highlighted that whereas a few years ago, there were more companies that seemed suitable for IPOs, the current crop of viable IPO candidates is relatively minimal. Younger businesses, particularly those yet to reach profitability, face more obstacles when trying to enter the public market.

For investors, profitability remains a critical point, an expectation that can't always be met, even by potential IPO stars. Omada Health, for example, has continued to report financial losses, revealing a $9.4 million shortfall in the first quarter of 2025.

Companies that aren't turning a profit may have to accept lower valuations to avoid their stocks falling post-IPO, according to PitchBook's DeGagne. Although Omada Health's initial public offering was valued at $1.1 billion—maintaining its past private valuation—its shares decreased shortly after the June IPO, currently at a market value of $875 million.

Startups universally are forced to reassess their market value considerations. For instance, while Hinge Health exhibited profitability with revenues more than twice Omada's, its IPO was pegged at a significant discount compared to its $6.2 billion private valuation from 2021. Nevertheless, its stock price has risen since May's public launch, now reflecting a market cap of over $3.6 billion.

Investors may exhibit leniency towards unprofitable healthcare firms focusing on AI, driven by the potential growth in this nascent tech sector. DeGagne points to industries experiencing ignited demand, such as Omada’s increasing engagement in obesity care amid rising medication prescriptions for conditions like weight loss.

Stowe remarked that the public listings of Hinge Health and Omada Health have been encouraging for the initial public offering market in general, despite uncertainties about whether more firms will rapidly capitalize on this opening.

"The condition of the market is currently quite robust. It won't necessarily benefit every company, but the backdrop is as favorable as it has been for some time. As long as the macroeconomic environment remains stable, potential IPO candidates are positioned well," he remarked.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts